Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

• ClinicalTrials.gov Identifier: NCT02758626
• Recruitment Status: Active, not recruiting
• First Posted: May 2, 2016
• Last Update Posted: November 13, 2019
• Sponsor: NYU Langone Health
• Collaborator: PTC Therapeutics
• Information provided by (Responsible Party): NYU Langone Health

Tracking Information

• First Submitted Date: April 4, 2016
• First Posted Date: May 2, 2016
• Last Update Posted Date: November 13, 2019
• Study Start Date: November 2016
• Estimated Primary Completion Date: December 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 28, 2016)

• Number of adverse events and serious adverse events related to ataluren [ Time Frame: Baseline to 3 months ]
• Number of adverse events and serious adverse events related to ataluren [ Time Frame: 3 months to 6 months ]
• Number of adverse events and serious adverse events related to ataluren [ Time Frame: 6 months to 1 year ]

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures (submitted: April 28, 2016): Seizure frequency from baseline after ataluren treatment in patients w/ CDKL5 or Dravet from daily seizure diary. [ Time Frame: Baseline, 3 months, 6 months, and 1 year ]
• Original Secondary Outcome Measures: Same as current

Current Other Pre-specified Outcome Measures (submitted: April 28, 2016)

• Change from baseline in cognitive behavior measured by Behavior Assessment System for Children [ Time Frame: Baseline, 3 months and 6 months ]
  Clinical and adaptive measures of personality and behavior using the Behavior Assessment System for Children: Third Edition (Sabaz 2003)
• Quality of Life (QOL) as assessed by the Quality of Life in Childhood Epilepsy (QOLCE) (Sabaz 2003) [ Time Frame: Baseline, 3 months and 6 months ]

• Original Other Pre-specified Outcome Measures: Same as current

Descriptive Information

• Brief Title: Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
• Official Title: A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome
• Brief Summary: This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1 will be followed by a 4-week Washout Period. Based on ataluren PK and pharmacodynamic data, the 4-week washout period is deemed an appropriate length of time to eliminate any ataluren drug effects. Following the Washout Period, patients will crossover to receive the opposite treatment during Treatment Period 2 as follows: Patients receiving ataluren during Treatment Period 1 will receive placebo during Treatment Period 2. Patients receiving placebo during Treatment Period 1 will receive ataluren during Treatment Period 2.
• Detailed Description: Investigators will try to characterize the safety profile of ataluren in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and evaluate changes in convulsive and/or drop seizure frequency from Baseline following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation. Investigators will measure changes in minor seizure types (absence, myoclonic, complex partial/focal dyscognitive) following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and changes from Baseline in cognitive, motor, and behavioral function as well as QOL following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Epilepsy

Intervention

• Drug: ataluren
  Powder formulation
  Other Name: PTC124
• Drug: Placebo
  Powder formulation

Study Arms

• Active Comparator: Ataluren Followed By Placebo
  Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
  Interventions:

  • Drug: ataluren
  • Drug: Placebo
• Active Comparator: Placebo Followed by Ataluren
  Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
  Interventions:

  • Drug: ataluren
  • Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: April 28, 2016): 16
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2022
• Estimated Primary Completion Date: December 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 2 years old and ≤ 12 years old, male or female, at Week 0 (at time informed consent/assent is signed)

2. Documentation of a diagnosis of Dravet syndrome or CDKL5 deficiency resulting from a nonsense mutation in 1 allele, as evidenced by medical records, genetic testing, and the following clinical feature:

   a. Failure to control seizures despite appropriate trial of 2 or more AEDs at therapeutic doses

3. Between 1 to 3 baseline AEDs at stable doses for a minimum for 4 weeks prior to the Baseline visit

   a. Vagus nerve stimulator (VNS), ketogenic diet, and modified Atkins diet do not count towards this limit but must be unchanged for 3 months prior to enrollment (Baseline).

4. VNS must be on stable settings for a minimum of 3 months prior to the Baseline visit
5. If on ketogenic or modified Atkins diet, must be on stable ratio for a minimum of 3 months prior to the Baseline visit
6. Written consent obtained from the patient or patient's legal representative must be obtained prior to performing any study procedures
7. Minimum of 6 convulsive or drop seizures with duration > 3 seconds over the 4 weeks of diary screening prior to randomization and ≥ 6 convulsive or drop seizures with duration > 3 seconds during the 4 weeks from Screening to Baseline.

Exclusion Criteria:

1. Patient is < 2 years old or ≥ 12 years old
2. Epilepsies associated with genetic disorders other than Dravet syndrome or CDKL5 deficiency
3. Patient has Dravet or CDKL5 genetic mutations that are NOT nonsense mutations
4. Felbatol has been initiated within the past 12 months prior to the Screening Visit
5. Patients who are currently or have participated in clinical trials in the 30 days prior to enrollment (Baseline Visit)
6. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition), medical history, physical findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
7. Ongoing intravenous administration of aminoglycosides or vancomycin.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years to 12 Years (Child)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02758626
• Other Study ID Numbers: 15-00426
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Responsible Party: NYU Langone Health
• Study Sponsor: NYU Langone Health
• Collaborators: PTC Therapeutics

Investigators

• Principal Investigator: Orrin Devinsky, MD; NYU

• PRS Account: NYU Langone Health
• Verification Date: November 2019